Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and biosimilar medicines. Our companies produce and distribute the medicines that make up more than 90% of all prescriptions filled in the United States – but at just 16% of total prescription drug spending. Our industry is an indispensable pillar of our national healthcare system.
Through our membership in the industry’s trade association, the Association for Accessible Medicines, we promote marketplace competition and support strategic enhancements to the Food and Drug Administration’s (FDA) generic drug and biosimilar approval process. We do this for one purpose: to put affordable medicines within the reach of patients who need them. Every dollar saved at the pharmacy counter is a dollar that patients can spend on life’s essentials and other pursuits — or put away for future use. We help patients live better lives,
and we do so in a way that saves precious resources for patients, taxpayers, and our economy.
The practices discussed in the Association for Accessible Medicines’ (AAM) Code of Business Ethics. represent behaviors that our companies have been demonstrating for years. And yet, it is incumbent on us to declare to our patients and customers the values upon which our industry is based, and the ethical and business standards upon which we are committed to operating with other members of the healthcare ecosystem.
The Association of Accessible Medicines (AAM) Code of Business Ethics is applicable to the operation of generic drug and biosimilar companies who adopt the Code in the United States and interactions with United States healthcare professionals. AAM’s Board of Directors has approved this Code.